Saatja: <
[email protected]>
Saadetud: 01.03.2019 18:03
Koopia: <
[email protected]>
Teema: WHO: C.L.6.2019 (SAGE IVD)
Manused: C.L.6.2019 (SAGE IVD).pdf; C.L.6.2019 Arabic.pdf; C.L.6.2019 Chinese.pdf;
C.L.6.2019 French.pdf; C.L.6.2019 Russian.pdf; C.L.6.2019 Spanish.pdf
Dear Member States of the World Health Organization,
Please find attached, in the six official languages, C.L.6.2019 regarding the second meeting of
the Strategic Advisory Group of Experts on In Vitro Diagnostics which will take place from
18 to 22 March 2019.
Best regards,
Department of Governing Bodies
World Health Organization
20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT
Ref.: C.L.6.2019
The World Health Organization (WHO) presents its compliments to Member States and
Associate Members and has the honour to refer to C.L.29.2018 regarding the Strategic Advisory
Group of Experts on In Vitro Diagnostics (SAGE IVD).
In 2017 WHO established a Strategic Advisory Group of Experts on In Vitro Diagnostics
(SAGE IVD) charged with developing a List of Essential In Vitro Diagnostics (EDL) and
providing advice to WHO on all matters related to IVDs.
Member States are invited to the open session of the second meeting of the SAGE IVD
which will be held from 18 to 22 March 2019. This open session will take place on
18 March 2019 from 08:30 to 16:00 in WHO headquarters (EB room) and is also open to
non-State actors in official relations with WHO and IVD industry associations.
The subsequent closed sessions (from 19 to 22 March) are expected to:
• review suggested changes to the existing EDL entries based on requests made by
WHO disease programmes and external stakeholders;
• discuss the public comments to new submissions to the EDL;
• discuss the new tests to be added to the 2nd edition of the EDL;
• discuss the EDL country implementation plan and determine the way forward;
• provide recommendations on considerations for future EDL editions;
• review the results of the WHO Prequalification prioritization consultation.
Member States interested to participate in the open session of the SAGE IVD meeting are
requested to register using the following link: http://reg.unog.ch/e/OPENSAGEIVD by
15 March 2019.
The session will also be live streamed. More information is available at:
https://www.who.int/medical_devices/diagnostics/selection_in-vitro/selection_in-vitro-
meetings/sage-ivd-2nd-meeting/en/.
Questions can be addressed by email to
[email protected].
The World Health Organization takes this opportunity to renew to Member States and
Associate Members the assurance of its highest consideration.
GENEVA, 1 March 2019